| Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors JF Shern, L Chen, J Chmielecki, JS Wei, R Patidar, M Rosenberg, ... Cancer discovery 4 (2), 216-231, 2014 | 746 | 2014 |
| The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation AS Brohl, DA Solomon, W Chang, J Wang, Y Song, S Sindiri, R Patidar, ... PLoS genetics 10 (7), e1004475, 2014 | 448 | 2014 |
| PAX3–FOXO1 establishes myogenic super enhancers and confers BET bromodomain vulnerability BE Gryder, ME Yohe, HC Chou, X Zhang, J Marques, M Wachtel, ... Cancer Discovery 7 (8), 884-899, 2017 | 284 | 2017 |
| Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers FJ Lowery, S Krishna, R Yossef, NB Parikh, PD Chatani, N Zacharakis, ... Science 375 (6583), 877-884, 2022 | 260 | 2022 |
| Genomic classification and clinical outcome in rhabdomyosarcoma: a report from an international consortium JF Shern, J Selfe, E Izquierdo, R Patidar, HC Chou, YK Song, ME Yohe, ... Journal of Clinical Oncology 39 (26), 2859-2871, 2021 | 149 | 2021 |
| MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma ME Yohe, BE Gryder, JF Shern, YK Song, HC Chou, S Sindiri, A Mendoza, ... Science translational medicine 10 (448), eaan4470, 2018 | 142 | 2018 |
| Recurrent inactivating RASA2 mutations in melanoma R Arafeh, N Qutob, R Emmanuel, A Keren-Paz, J Madore, A Elkahloun, ... Nature genetics 47 (12), 1408-1410, 2015 | 131 | 2015 |
| Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer N Roper, AL Brown, JS Wei, S Pack, C Trindade, C Kim, O Restifo, S Gao, ... Cell reports medicine 1 (1), 2020 | 130 | 2020 |
| Breast cancers are immunogenic: immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes N Zacharakis, LM Huq, SJ Seitter, SP Kim, JJ Gartner, S Sindiri, VK Hill, ... Journal of Clinical Oncology 40 (16), 1741-1754, 2022 | 115 | 2022 |
| MultiDimensional ClinOmics for precision therapy of children and adolescent young adults with relapsed and refractory cancer: a report from the center for cancer research W Chang, AS Brohl, R Patidar, S Sindiri, JF Shern, JS Wei, YK Song, ... Clinical cancer research 22 (15), 3810-3820, 2016 | 115 | 2016 |
| Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma JS Wei, IB Kuznetsov, S Zhang, YK Song, S Asgharzadeh, S Sindiri, ... Clinical Cancer Research 24 (22), 5673-5684, 2018 | 110 | 2018 |
| Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer N Roper, MJ Velez, A Chiappori, YS Kim, JS Wei, S Sindiri, N Takahashi, ... Nature communications 12 (1), 3880, 2021 | 107 | 2021 |
| APOBEC mutagenesis and copy-number alterations are drivers of proteogenomic tumor evolution and heterogeneity in metastatic thoracic tumors N Roper, S Gao, TK Maity, AR Banday, X Zhang, A Venugopalan, ... Cell reports 26 (10), 2651-2666. e6, 2019 | 105 | 2019 |
| Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor–engineered T cells targeting common p53 neoantigens in human solid tumors SP Kim, NR Vale, N Zacharakis, S Krishna, Z Yu, B Gasmi, JJ Gartner, ... Cancer immunology research 10 (8), 932-946, 2022 | 102 | 2022 |
| Germline CARD11 Mutation in a Patient with Severe Congenital B Cell Lymphocytosis AS Brohl, JR Stinson, HC Su, T Badgett, CD Jennings, G Sukumar, ... Journal of clinical immunology 35, 32-46, 2015 | 98 | 2015 |
| The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas A Pemov, H Li, R Patidar, NF Hansen, S Sindiri, SW Hartley, JS Wei, ... Oncogene 36 (22), 3168-3177, 2017 | 97 | 2017 |
| Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1–associated atypical … A Pemov, NF Hansen, S Sindiri, R Patidar, CS Higham, E Dombi, ... Neuro-oncology 21 (8), 981-992, 2019 | 91 | 2019 |
| Insights into pediatric rhabdomyosarcoma research: Challenges and goals ME Yohe, CM Heske, E Stewart, PC Adamson, N Ahmed, CR Antonescu, ... Pediatric blood & cancer 66 (10), e27869, 2019 | 78 | 2019 |
| Vangl2/RhoA signaling pathway regulates stem cell self-renewal programs and growth in rhabdomyosarcoma MN Hayes, K McCarthy, A Jin, ML Oliveira, S Iyer, SP Garcia, S Sindiri, ... Cell stem cell 22 (3), 414-427. e6, 2018 | 71 | 2018 |
| Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma IM Tenente, MN Hayes, MS Ignatius, K McCarthy, M Yohe, S Sindiri, ... Elife 6, e19214, 2017 | 69 | 2017 |
Javed KhanDeputy Branch Chief Genetics Branch, Senior Investigator, Center for Cancer Research, NCI, NIHVerified email at mail.nih.gov
